Probiodrug AG to
Publish its Third Quarter 2017 Business Update on 30 November
2017
HALLE (SAALE),
Germany, 23 November 2017 - Probiodrug AG (Euronext Amsterdam:
PBD), a biopharmaceutical company developing novel therapeutic
solutions to treat Alzheimer's disease (AD), will publish its
third quarter business update for the period ended 30 September
2017 on Thursday, 30 November 2017, in the form of an interim
management report.
The Third Quarter 2017 Business
Update will be available for download on the company website
(http://www.probiodrug.de/investors/reports-and-presentations/).
###
For more
information please contact:
Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de
Hume
Brophy
Conor Griffin, Alexander Protsenko, Jonothan Blackbourn
Tel: +44 (0) 20 7862 6381
Email: probiodrug@humebrophy.com
The Trout
Group
Tricia Truehart
Tel: +1 646 378-2953
Email: ttruehart@troutgroup.com
MC Services AG
Anne Hennecke, Caroline Bergmann
Tel: +49 (0) 211 529 252 20
Email: probiodrug@mc-services.eu
Notes to
Editors:
About Probiodrug
AG
Headquartered in Halle (Saale), Germany, Probiodrug AG (Euronext
Amsterdam: PBD) is a biopharmaceutical company focused on the
development of new therapeutic products for the treatment of
Alzheimer's disease (AD). Probiodrug has identified a new
therapeutic concept linked to disease initiation and progression.
The development approaches are targeting a key neuro/synaptotoxic
component of the pathology, pyroglutamate-Abeta (pGlu-Abeta, N3pG)
as a therapeutic strategy.
Probiodrug's lead product
candidate, PQ912, is a highly specific and potent inhibitor of
Glutaminyl Cyclase (QC), which has shown therapeutic effects in AD
animal models. A Phase-1 study in healthy young and elderly
volunteers revealed a dose dependent exposure and showed good
safety and tolerability up to the highest dose showing >90%
target occupancy in the spinal fluid. In June 2017 Probiodrug
announced top-line data of the Phase-2a SAPHIR trial of its lead
candidate (Probiodrug announces encouraging results of the Phase 2a
SAPHIR Study ). The positive effects seen on secondary exploratory
efficacy markers are strongly supporting (a) the hypothesis of
pGlu-Abeta being synaptotoxic and (b) the therapeutic concept
pursued by Probiodrug. The study revealed a positive benefit risk
ratio of PQ912 and provides important guidance how to move forward
in the development of PQ912 as a disease-modifying drug for AD.
Altogether, the results make the program highly attractive for
further development.
Complementary to the small
molecule PQ912 inhibiting the formation of the synaptotoxic agent
pGlu-Abeta, the company is developing PBD-C06, an
anti-pGlu-Abeta-specific monoclonal antibody.
The Company has medical use and composition of matter patents
related to the inhibition of QC and anti-pGlu-Abeta-specific
monoclonal antibodies, and has, in the Company's view, a leading
position in this field of research.
Founded in 1997 by Hans-Ulrich
Demuth and Konrad Glund, the company successfully developed a novel
therapeutic concept for diabetes - the DP4 inhibitors - which
provided the basis for a novel class of antidiabetics - the
gliptins. Its core capabilities are based on its long-standing
expertise in the elucidation of the structure and function of
enzymes involved in the modification of proteins and peptides,
which play a central role in pathological conditions.
Today, Probiodrug aims to become a
leading company in the development of AD treatments and to thereby
provide a better life for Alzheimer's disease patients.
www.probiodrug.de
About Alzheimer's
disease
Alzheimer's disease is a neurological disorder, which is the most
common form of dementia, and ultimately leads to death. Because
Alzheimer's disease cannot be cured and is degenerative, the
affected patients must increasingly rely on others for assistance.
Today, 47 million people live with dementia worldwide, and this
number is projected to treble to more than 131 million by 2050, as
populations age. Dementia also has a huge economic impact.
Alzheimer's has an estimated, global societal cost of US$ 818
billion, and it will become a trillion dollar disease by 2018.
(World Alzheimer Report 2016).
Forward Looking Statements
Information set forth in this press release
contains forward-looking statements, which involve a number of
risks and uncertainties. The forward-looking statements contained
herein represent the judgment of Probiodrug AG as of the date of
this press release. Such forward-looking statements are neither
promises nor guarantees, but are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change
in our expectations or any change in events, conditions or
circumstances on which any such statement is based.